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Abstract  
 
Splicing defects are among the most frequent pathogenic mechanisms underlying 
genetic diseases. Thus, the development of therapeutic strategies targeting RNA 
represents an important opportunity to correct faulty splicing, opening the prospects 
of treatment for numerous genetic disorders. The vast majority of RNA-based 
approaches have exploited, in vitro and in vivo, the use of antisense oligonucleotides 
or modified U1 snRNAs to overcome different splicing mutations.  
Lysosomal storage disorders (LSDs) are a group of inherited diseases that can result in 
severe and progressive pathology due to a specific lysosomal dysfunction. In several 
patients, splicing mutations have been identified and are frequently associated with 
particular types of LSDs worldwide. Some treatment strategies are already available 
for conventional LSDs, but yet with some limitations. Therefore, for splicing 
mutations, splicing therapeutics might represent a crucial option or an important 
adjunct of other treatments. 
In this study, we have used a modified U1 snRNA that completely matches the splice 
donor site of HGSNAT gene exon 2, which corrected the effect of the common 5’ 
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splice site mutation c.234+1G>A in Mucopolysaccharidosis IIIC (1). In another 
approach using an antisense oligonucleotide (AO) we have succeeded in the 
correction of the c.66G>A splicing mutation in CSTB gene (Unverricht–Lundborg 
disease). Besides that, we have performed the functional analysis of some IDS gene 
splicing mutations (Mucopolysaccharidosis II)  and used AOs to exploit an alternative 
therapy for one of those mutations (c.1122C>T on exon 8) (2).  
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